About Neornat

History

04
Selected for the Drug Candidate Track of the Korea Drug Development Fund 「Drug R&D Ecosystem Development Research」 Program (KRW 1.2 billion / 2026–2028)
Selected for the Ministry of SMEs and Startups’ 「Startup Leap Package」 (KRW 210 million / 2026)
01
Entered into a financial advisory agreement with InDeal Co., Ltd., a strategic advisory firm specializing in fundraising and technology commercialization

12
In-licensed patented technology for early gastric cancer diagnosis from The Catholic University of Korea Industry–Academic Cooperation Foundation (CUK-IACF)
09
Celebrated the 5th anniversary of NEORNAT Co., Ltd.
07
Signed an MOU with MediRama Inc., a clinical development specialist, for 「drug development and clinical collaboration」
06
Initiated joint R&D of a lung cancer gene therapy with Certest, a company specializing in lung cancer delivery technologies
Submitted a pre-IND consultation request to the Ministry of Food and Drug Safety (MFDS) for NRT-YHD_001, an RNA immunotherapy for hepatocellular carcinoma
05
Selected for the 「2025 Startup-Centered University Program (Preliminary Startup Track)」, administered by the Ministry of SMEs and Startups (KRW 100 million / 2025)
01
Signed an MOU with Beyond Bridge & Co., a specialist firm in global licensing, technology commercialization, and fundraising

06
Selected for the Ministry of SMEs and Startups’ 「POST-TIPS」 Program (KRW 430 million / 2024–2025)
05
CEO Suk Woo Nam was invited to speak at the special session, 「Next-Generation Drug Platform Development Strategies」 at BIO KOREA 2024
04
Selected for KDDF’s 「Global Technology Transfer and Co-Development Support Program」 (KRW 100 million / 2024)

12
Entered into an agreement with Liberi Group, a global business development firm, to pursue technology transfer and co-development
Completed a KRW 3.5 billion Series A financing
07
Signed a joint R&D agreement with CellArtgen Co., Ltd., a biomaterials specialist, for an RNA-based liver cancer gene therapy
04
Selected for the Preclinical Track of the Korea Drug Development Fund (KDDF) 「Drug R&D Ecosystem Development Research」 Program (KRW 2.0 billion / 2023–2025)
02
Signed an MOU with AIMS Biosciences Co., Ltd., a preclinical and clinical development specialist, to support IND approval for NRT-YHD_001

09
Established NEORNAT Corporate R&D Center
06
Selected as a Top 5 finalist and named as a Best company at SteinTech Bio Season 1
03
Completed a KRW 2.7 billion Series A financing
02
Signed an MOU with LabGenomics Co., Ltd., a molecular diagnostics specialist, to develop RNA-based early cancer diagnostics

12
In-licensed patented technology for anticancer drug candidates from The Catholic University of Korea Industry–Academic Cooperation Foundation (CUK-IACF)
11
Entered into an agreement with Algok Bio Inc. concerning preferred negotiating rights for NRT-YHD_001, a liver cancer therapeutic
06
Selected for the Ministry of SMEs and Startups’ 「TIPS Program」 (KRW 550 million / 2021–2023)

11
In-licensed patented technology for anticancer drug candidates and in vitro diagnostics from The Catholic University of Korea Industry–Academic Cooperation Foundation (CUK-IACF)
09
Established NEORNAT Co., Ltd.